Tirzepatide vs Semaglutide: Mounjaro vs Ozempic Compared for Vietnam 2026
Last updated September 2026
This is harm reduction education, not medical advice
This guide presents clinical data and community experience to help you make an informed decision. It is not a prescription recommendation. Talk to a doctor before starting any GLP-1 medication.
22.5%
Tirzepatide avg. weight loss
14.9%
Semaglutide avg. weight loss
Once
Weekly
Dosing for both
You have a doctor appointment coming up for a weight loss consultation in Ho Chi Minh City or Hanoi. You have done enough reading to know the real choice is between tirzepatide (sold as Mounjaro or Zepbound) and semaglutide (sold as Ozempic or Wegovy). You want to walk in already knowing which one to ask for.
Both are GLP-1 receptor agonists. Both work. Both are used by tens of millions of people worldwide. The question is which one is right for your situation. That answer depends on three things: how much weight loss you need, how sensitive you are to GI side effects, and what budget you are working with.
This guide gives you the actual decision framework. The data is real, and it is laid out in full so you can weigh the tradeoffs yourself. This is for people who want to understand those tradeoffs before they sit down with a clinician, who is the one to decide.
For the full technical profiles on each molecule, see the semaglutide peptide profile and the tirzepatide peptide profile. This guide focuses on the comparison and the decision.
The Quick Answer
Tirzepatide produces about 50% more weight loss than semaglutide in head-to-head clinical data. For a 90 kg person, that gap translates to roughly 6 kg of additional weight loss over a year. The efficacy difference is real, consistent across multiple trials, and large enough to matter in practice.
In SURPASS-2, the head to head diabetes trial, nausea ran 17 to 22% across the tirzepatide groups against 18% on semaglutide 1 mg (trial doses, not a recommendation). SURPASS-2 was not designed to show which drug is better tolerated, so those figures do not settle which one is easier to tolerate. GIP co-agonism has been proposed as a mechanism for tirzepatide, but no trial shows it reduces nausea. Tolerance varies from person to person, and no trial predicts in advance who will do better on which.
Semaglutide has about five years more post-approval experience than tirzepatide. Ozempic has been in use since 2017, so it has accumulated more real-world exposure than the newer drug. It is also significantly cheaper at both the pharmacy and research-grade level.
Both are approved GLP-1 medicines with large trial programs. The decision comes down to priorities that differ from person to person: cost, how much weight loss is needed, supply in Vietnam, tolerability, and medical history. Semaglutide is the cheaper, longer-studied option; tirzepatide produced the larger average weight loss in the head to head. Both drugs now have a published cardiovascular outcome trial, though tirzepatide's (SURPASS-CVOT) compared it against dulaglutide, not semaglutide, and did not show superiority. Which of those weighs most for a given person, and whether either drug is appropriate at all, is a prescriber decision, and this page does not make it.
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
What Each One Actually Is
Semaglutide is a single-agonist GLP-1 receptor drug developed by Novo Nordisk. It mimics the GLP-1 hormone your gut releases after eating, which tells your brain you are full and slows gastric emptying. It was FDA approved in 2017 as Ozempic for type 2 diabetes, and in 2021 as Wegovy specifically for obesity at a higher dose. That gives it about five years more post-approval experience than tirzepatide.
Tirzepatide is a dual-agonist drug targeting both the GLP-1 receptor AND the GIP receptor, developed by Eli Lilly. GIP is a second gut hormone involved in fat storage, insulin response, and energy balance. Tirzepatide targets the GLP-1 and GIP receptors and produced greater mean weight reduction than semaglutide in SURPASS-2 and SURMOUNT-5. It was FDA approved in 2022 as Mounjaro for diabetes and in 2023 as Zepbound specifically for obesity.
The GIP addition is the key difference. It is not just a "more powerful semaglutide." It acts on a second receptor as well as GLP-1. For the full technical breakdown of each, see the semaglutide profile and tirzepatide profile.
Efficacy Head to Head
STEP 1 is the pivotal semaglutide obesity trial: 1961 adults randomised to semaglutide 2.4 mg weekly or placebo for 68 weeks, mean body weight change 14.9% against 2.4% on placebo, with 50.5% of the semaglutide group losing 15% or more (trial dose, not a recommendation). Source: Wilding et al., New England Journal of Medicine, 2021, PMID 33567185. On the semaglutide side, dosing below the labelled 0.25 mg starting step is the practice explained in the microdosing semaglutide guide.
SURMOUNT-1 is the tirzepatide equivalent: mean body weight change at 72 weeks of 15.0% at 5 mg weekly, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo, with 57% of the 15 mg group losing 20% or more (trial doses, not a recommendation). Source: Jastreboff et al., New England Journal of Medicine, 2022, PMID 35658024. For the tirzepatide side on its own, our breakdown of tirzepatide before and after results covers the week-by-week timeline, body composition, waist change, and what happens after stopping.
SURMOUNT-5 put both drugs in a direct comparison: 751 adults with obesity and without diabetes, maximum tolerated tirzepatide (10 or 15 mg) against maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks, 20.2% against 13.7% mean weight change and 18.4 cm against 13.0 cm of waist circumference (trial doses, not a recommendation). Source: Aronne et al., New England Journal of Medicine, 2025, PMID 40353578.
For a sense of scale, a 90 kg person losing 13.7% loses about 12.3 kg, and the same person losing 20.2% loses about 18.2 kg, a difference of roughly 6 kg. That arithmetic applies to the trial averages, not to any individual: every one of these trials reports a wide spread around the mean, all three were funded by the manufacturer, and none of them tested a switch from one drug to the other.
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
Side by Side Comparison
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Mean weight change in the pivotal obesity trial (trial dose, not a recommendation) | 14.9% at 2.4 mg weekly, 68 weeks (STEP 1) | 20.9% at 15 mg weekly, 72 weeks (SURMOUNT-1) |
| Mean weight change head to head (trial dose, not a recommendation) | 13.7% at 72 weeks (SURMOUNT-5) | 20.2% at 72 weeks (SURMOUNT-5) |
| Mechanism | GLP-1 agonist only | GLP-1 + GIP dual agonist |
| Labeled dosing frequency (approved label) | Once weekly (Ozempic) | Once weekly (Mounjaro) |
| Labeled starting dose (approved label) | 0.25 mg weekly for 4 weeks (Ozempic) | 2.5 mg weekly for 4 weeks (Mounjaro) |
| Labeled maximum dose (approved label) | 2 mg weekly (Ozempic), 2.4 mg weekly (Wegovy) | 15 mg weekly (Mounjaro, adults) |
| GI adverse events in the head to head diabetes trial (trial dose, not a recommendation) | Nausea 18%, diarrhea 12%, vomiting 8% (SURPASS-2) | Nausea 17 to 22%, diarrhea 13 to 16%, vomiting 6 to 10% (SURPASS-2) |
| FDA approval year | 2017 (diabetes) / 2021 (obesity) | 2022 (diabetes) / 2023 (obesity) |
| Real-world safety data | Diabetes 2017, obesity 2021 | Diabetes 2022, obesity 2023 |
| Cardiovascular outcome trial (trial result, not a recommendation) | SUSTAIN-6 (versus placebo): composite of CV death, non-fatal MI or non-fatal stroke, hazard ratio 0.74, but retinopathy complications hazard ratio 1.76 | SURPASS-CVOT (2025): composite of CV death, MI or stroke, hazard ratio 0.92, noninferior but not superior to dulaglutide (not semaglutide) |
| Brand names | Ozempic / Wegovy | Mounjaro / Zepbound |
| Vietnam pharmacy availability | Consistent (Ozempic registered) | No registered route (Mounjaro not registered) |
| Research-grade pricing | Lower | Higher |
| Length of post-approval record | Approved for diabetes since 2017, obesity since 2021 | Approved for diabetes since 2022, obesity since 2023 |
Tirzepatide carries the larger average weight change in every trial that has measured both. The rows underneath cut the other way. Both drugs now have a published cardiovascular outcome trial: semaglutide's SUSTAIN-6 reported a lower composite event rate but more retinopathy complications, both versus placebo, while tirzepatide's SURPASS-CVOT compared it against dulaglutide rather than semaglutide and was noninferior but not superior. Semaglutide also has the longer post-approval record and the more consistent supply in Vietnam, and the pricing gap is real over a multi-month course.
Those tradeoffs are what a prescriber weighs against a specific person: what they are being treated for, what else they take, what their eyes and pancreas and gallbladder history look like, and what is actually stocked where they live. This page does not rank the two or nominate a starting drug.
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
Side Effects and Tolerability
The most common adverse events for both drugs are gastrointestinal: nausea, diarrhea, constipation and vomiting. The SURMOUNT-1 and SURMOUNT-5 reports both state that these occurred primarily during dose escalation, and the approved labels specify a starting dose held for 4 weeks before any increase as a measure to reduce them (approved label).
SURPASS-2, the head to head diabetes trial, reported nausea in 17 to 22% of the tirzepatide groups against 18% on semaglutide 1 mg, diarrhea in 13 to 16% against 12%, vomiting in 6 to 10% against 8%, and serious adverse events in 5 to 7% against 3% (trial doses, not a recommendation). SURPASS-2 was not designed to test which drug is better tolerated, and the earlier version of this page was wrong to claim tirzepatide was easier to tolerate. Source: PMID 34170647.
Individual response varies well beyond those group rates. Some people tolerate semaglutide and struggle with tirzepatide, and some find the reverse. No published trial identifies in advance who will fall where.
Both drugs carry the same serious risk warnings: medullary thyroid carcinoma (MTC), pancreatitis, gallbladder disease, and severe hypoglycemia in people on insulin. Both labels carry warnings for these events; the trials do not establish which drug has the lower rare-event risk. These are class-level warnings, not brand-specific ones.
People who stop semaglutide because of intolerable nausea often ask whether tirzepatide is the answer. No trial has studied that population, so this page cannot say, and the head to head rates above give no reason to expect it. What happens next after a drug is not tolerated is a prescriber decision, including whether the titration pace or the drug itself needs to change. See the GLP-1 side effect management guide for what the labels and trials say about the first weeks.
Vietnam Availability Reality
Ozempic (semaglutide) is registered with Vietnam's Drug Administration (DAV) and consistently available at major international hospitals. FV Hospital, Vinmec, Raffles Medical, and City International Hospital all carry it. Larger pharmacies in HCMC and Hanoi also stock it. A prescription from a Vietnamese doctor or international hospital is required for the pharmacy route. Wegovy is not registered as of early 2026 but appears occasionally at international hospitals.
Mounjaro (tirzepatide) holds no Vietnamese marketing registration, so there is no registered hospital or pharmacy route for it. Zepbound, the same molecule under its obesity label, is not registered either. Ozempic is the GLP-1 the pharmacy route actually reaches, and research-grade tirzepatide is the channel that exists for tirzepatide itself. Registration status changes, so confirm it with the Drug Administration of Vietnam or a licensed pharmacy rather than a blog, including this one.
Research-grade versions of both molecules are available through the same supplier network at significantly lower cost than pharmacy pricing. The supplier verification process and COA requirements are identical for both. Most suppliers in the community-vetted network stock both.
For current pricing, hospital contacts, and the research-grade sourcing process, see the Semaglutide Vietnam 2026 guide and the Tirzepatide Vietnam 2026 guide for specifics on each.
Who Should Choose What
Profile 1: New to GLP-1s, cost is a factor
What is on the record: semaglutide has the longer post-approval history (diabetes 2017, obesity 2021), more consistent pharmacy supply in Vietnam, and lower cost at both pharmacy and research-grade pricing. Both drugs now have a published cardiovascular outcome trial. What is not on the record is whether starting here is better for a given person. That is a prescribing decision, and this page does not make it.
Profile 2: New to GLP-1s, weight change is the priority
What is on the record: in the head to head obesity trial, tirzepatide produced 20.2% mean weight change against 13.7% on semaglutide at 72 weeks (SURMOUNT-5, trial doses, not a recommendation). The head to head diabetes trial (SURPASS-2) was not designed to show which drug is better tolerated. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) tested it against dulaglutide, not semaglutide, and did not show superiority, and supply in Vietnam is less reliable. Weighing those against each other for a specific person is a prescriber decision.
Profile 3: Already on semaglutide, weight loss has stalled
Switching is the most commonly reported path in the community (community practice, no trial). No published trial has enrolled people who plateaued on semaglutide and measured what a switch does, so the claim that GIP activation breaks a plateau is a mechanism argument rather than a result. A stall in a prescribed treatment is something to raise with the prescriber, not to resolve from a guide.
Profile 4: Already on semaglutide and it is working
The trial gap above is an average across groups, not a shortfall in any particular person who is already responding. Switching means a different adverse event profile, a fresh titration, and higher cost, with no trial evidence on what it does for someone who is already at their target. Whether to change a treatment that is working is a prescriber decision.
For Research-Grade Buyers
If you are already committed to the research-grade route, the decision framework from the previous sections still applies. Research-grade tirzepatide is sold under the same molecule name, but the clinical trials measured the regulated pharmaceutical products, and their results cannot be assumed to carry over to research-grade material. Research-grade supply is not approved for human use, and whether a given vial contains what its label says, at the strength and purity claimed, is not established by those trials. A certificate of analysis is documentation supplied by the seller; an independent third-party lab test of the same batch is the stronger check of that identity and strength. Neither makes research-grade material equivalent to an approved medicine, and neither covers sterility, storage or handling.
The cost gap narrows at research-grade pricing. Tirzepatide is still more expensive per mg than semaglutide, though both sit well below what a registered pharmacy charges for branded semaglutide. Most suppliers in the community supply index stock both. Availability is generally more reliable than the pharmacy route for semaglutide, which is the only one of the two with a registered pharmacy route in Vietnam.
For any research-grade purchase, an independent third-party lab test of the same batch is the strongest available check of a specific vial's claimed identity, strength and purity, stronger than a seller-supplied certificate of analysis, and even then it does not make research-grade material equivalent to an approved product or cover sterility, storage and chain-of-custody risks. Read the COA verification guide before committing to any supplier.
The most commonly reported approach in the community is 2 to 3 months on semaglutide before considering tirzepatide (commonly reported in the community, no trial). No trial has compared that sequence against starting on either drug alone, so the reasoning behind it, adapting to GLP-1 agonism and establishing a baseline, is a rationale rather than a measured result.
Disclaimer: this is education, not a plan, and whether either drug is appropriate at all, and in what order, is a decision a licensed prescriber makes.
For the Vietnam-specific legal and regulatory context, see the peptide legality guide and the GLP-1 Vietnam overview.
How to Switch Between Them
The Mounjaro label specifies the tirzepatide escalation, and it does not vary with what a person took before: the same starting dosage and the same stepwise increases apply whether or not someone has already been on another GLP-1 (approved label). This page does not reproduce the full escalation, because it belongs in the prescribing information a clinician works from. Source: Mounjaro prescribing information, DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
Disclaimer: this is education, not a plan, and a licensed prescriber decides whether and how to switch.
What the label does not specify is a washout interval between one GLP-1 and another, because no trial has established one. The 7 day figure that circulates is community practice, no trial, reasoned from semaglutide's roughly one week half-life. Community reports also describe more GI trouble in the first month when the labeled starting step is skipped (community practice, no trial). When to stop one drug and start the other, and how fast to step up, is a prescriber decision, and this page does not publish a switching schedule.
Disclaimer: this is education, not a plan, and a licensed prescriber decides whether and how to switch.
Switching from tirzepatide back to semaglutide (less common, usually for cost reasons) is commonly reported to follow the same logic: a washout after the last dose, then reintroduction on semaglutide's labeled titration. No trial has established a switching sequence or washout interval here either.
Disclaimer: this is education, not a plan, and a licensed prescriber decides whether and how to switch.
No trial has tested the two drugs together and no label describes the combination, so nobody has measured what running both does. Retatrutide adds a third receptor target, glucagon, and reported a larger mean weight change than either drug in its phase 2 trial, but it has no regulatory approval in any market. See the full comparison of retatrutide vs tirzepatide.
What About Retatrutide?
Retatrutide is the triple agonist that adds glucagon receptor activation on top of GLP-1 and GIP. Its phase 2 obesity trial reported a mean weight change at 48 weeks of 24.2% in the 12 mg group against 2.1% on placebo, with 83% of that group losing 15% or more, and dose dependent increases in heart rate that peaked at 24 weeks (trial doses, not a recommendation). Source: Jastreboff et al., New England Journal of Medicine, 2023, PMID 37366315.
That phase 2 result is no longer the whole picture: phase 3 results have since been published, including TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2 in The Lancet, both in September 2026. Retatrutide still has no regulatory approval in any market, no label to cite, and no completed cardiovascular outcomes trial: ClinicalTrials.gov lists TRIUMPH-Outcomes (NCT06383390) with an estimated primary completion of February 2029. Lilly's TRIUMPH-3 release reported a pre-specified cardiovascular event analysis that was not statistically conclusive (hazard ratio 0.82, 95% CI 0.55 to 1.22, for 5-point MACE). What circulates outside trials is research chemical supply of unverified content.
This page does not rank an unapproved compound against two approved ones, in either direction. See the retatrutide vs tirzepatide comparison for the fuller evidence picture.
Sources: TRIUMPH-2, The Lancet, 29 September 2026; TRIUMPH-1, New England Journal of Medicine, 29 September 2026; ClinicalTrials.gov, TRIUMPH-Outcomes, NCT06383390; Eli Lilly, TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
The Bottom Line
Tirzepatide produced the larger mean weight change in every trial that has measured both, by about 6.5 percentage points in the head to head obesity comparison (SURMOUNT-5, trial doses, not a recommendation). That is the strongest thing that can be said for it, and it is a group average.
Semaglutide has the longer post-approval record, a published cardiovascular outcome trial (SUSTAIN-6, versus placebo, hazard ratio 0.74 on the composite outcome and 1.76 on retinopathy complications), lower cost, and more reliable supply in Vietnam. Tirzepatide now has one too, SURPASS-CVOT, which was noninferior but not superior to dulaglutide, a different comparator from semaglutide. Semaglutide's 14.9% mean weight change in STEP 1 is a substantial result on its own terms (trial dose, not a recommendation).
Both drugs have real tradeoffs and this page does not resolve them for anyone. Matching a drug to a person is what a prescriber is for.
None of this is medical advice. Both of these are prescription medications. Talk to a doctor before starting either one.
This guide is for educational purposes only. Tirzepatide and semaglutide are prescription medications. The clinical data cited comes from published trials. Individual results vary. Nothing here constitutes medical advice, diagnosis, or treatment recommendations. Consult a licensed physician before starting any medication.
Frequently Asked Questions
Which is better for weight loss, tirzepatide or semaglutide?
The pivotal obesity trials reported: Semaglutide 2.4 mg weekly, 14.9 percent mean body weight reduction at 68 weeks (STEP 1). Tirzepatide 15 mg weekly, 20.9 percent at 72 weeks (SURMOUNT-1). Direct comparison, 20.2 percent on tirzepatide against 13.7 percent on semaglutide at 72 weeks, a gap of about 6.5 percentage points (SURMOUNT-5) (trial doses, not a recommendation). Disclaimer: tirzepatide produced the larger average reduction in every trial that measured both, but these are group averages on the treatment regimen estimand in selected trial populations, alongside lifestyle intervention. They describe groups and not individuals, and a larger average does not make one drug appropriate for a given person. That is a prescribing decision.
Is Mounjaro or Ozempic available in Vietnam?
Ozempic (semaglutide) is registered with the DAV and consistently available at major international hospitals and larger pharmacies in HCMC and Hanoi. Mounjaro (tirzepatide) holds no Vietnamese marketing registration, so there is no registered hospital or pharmacy route for it. Research-grade versions of both are available through the supplier network at significantly lower cost.
Can I switch from semaglutide to tirzepatide?
Switching between these GLP-1 compounds is commonly reported in the community. The approach people describe is a washout after the last semaglutide dose, then reintroduction at the lowest labeled tirzepatide starting dose with the standard gradual titration the Mounjaro label sets out, on the reasoning that the GIP receptor is new territory for the body regardless of the prior semaglutide dose. No trial has established a switching sequence or washout interval. Disclaimer: this is education, not a plan. A licensed prescriber decides whether and how to switch.
Which has worse side effects, Mounjaro or Ozempic?
The SURPASS-2 head to head trial reported: Nausea 17 to 22 percent on tirzepatide (5, 10 and 15 mg weekly) against 18 percent on semaglutide 1 mg weekly, diarrhea 13 to 16 percent against 12 percent, vomiting 6 to 10 percent against 8 percent, serious adverse events 5 to 7 percent against 3 percent (trial doses, not a recommendation). Disclaimer: those rates come from a single open label 40 week trial in 1879 adults with type 2 diabetes (Frias et al., New England Journal of Medicine, 2021, PMID 34170647). They do not show tirzepatide being easier to tolerate than semaglutide, which is what this page previously claimed. Both products carry the same boxed warning for thyroid C-cell tumors, and both list pancreatitis and gallbladder disease. Group rates do not predict what one person will feel, and a reaction to a prescribed medicine belongs with the prescriber who started it.
How much does Mounjaro cost in Vietnam compared to Ozempic?
There is no like-for-like pharmacy comparison to make. Ozempic is registered in Vietnam and carries a real pharmacy price; Mounjaro holds no Vietnamese marketing registration, so there is no registered pharmacy price for it and no hospital route to point you at. The comparison that does exist is on the research-grade market, where tirzepatide generally runs higher than semaglutide. The Tirzepatide Vietnam 2026 guide and Semaglutide Vietnam 2026 guide carry the current figures for each.
Is research-grade tirzepatide the same as Mounjaro?
Research-grade tirzepatide is sold under the same molecule name, but that name is a label, not a guarantee. The clinical trials tested the regulated pharmaceutical product, which carries the pharmaceutical branding, defined excipients and an auto-injector pen; research-grade material is not approved for human use. Its identity, strength and sterility cannot be presumed from the molecule name. A certificate of analysis is documentation supplied by the seller; an independent third-party lab test of the same batch is the stronger check of identity and strength. Neither makes research-grade material equivalent to an approved medicine, and neither covers sterility, storage or handling.
Should I start with semaglutide or jump straight to tirzepatide?
The obesity trials measured: Semaglutide 2.4 mg weekly, 14.9 percent mean body weight reduction at 68 weeks against 2.4 percent on placebo (STEP 1, 1961 adults). Tirzepatide 15 mg weekly, 20.9 percent at 72 weeks (SURMOUNT-1). Head to head in adults with obesity and without diabetes, 20.2 percent on tirzepatide against 13.7 percent on semaglutide at 72 weeks (SURMOUNT-5, 751 adults) (trial doses, not a recommendation). Disclaimer: those are group averages from three separate trials run alongside lifestyle intervention (PMID 33567185, 35658024, 40353578). No trial has tested a sequence, so there is no evidence that beginning on one drug and moving to the other produces a better outcome than either alone. Which drug a person starts on is a prescribing decision that also weighs cost, local supply, tolerability and medical history. This page publishes the numbers, not the order.
Can I stack tirzepatide and semaglutide together?
No trial has tested the two together and no approved label describes the combination, so there is no evidence to report either way. Both act on the same GLP-1 receptor, which means running them together largely duplicates one mechanism rather than adding a second, and the absence of published data on the pair is not evidence that the pair is safe. Retatrutide usually comes up at this point. It remains investigational with no regulatory approval in any market, so it is an unavailable option rather than a stronger one. What to do when a single agent is not producing the hoped for result is a prescribing decision. The retatrutide vs tirzepatide comparison guide covers where that compound actually stands.